Plenary speakers

In 2000 Prof. Grasso obtained the “Laurea” in Chemistry in Catania (110/110 cum laude) from the University of Catania and in 2004 the PhD in Chemistry from the University of Nottingham (UK). After several post-docs he finally got a permanent position at the University of Catania in 2010 where he is currently employed as an Associate professor. He also has the National qualification to become a Full Professor. He is the ERASMUS coordinator within the Erasmus+ Program, Key Action 1 – Mobility for learners and staff-Higher Education Student and Staff Mobility with universities from France, Poland, UK, Germany and Portugal. Currently he is at the UNIVERSITE DE CERGY-PONTOISE as a visiting Professor. In 2020 he has been elected President of the Bachelor Course in Chemistry at the University of Catania.

The research of Prof. Grasso is focused on the study of molecular interactions between biomolecules involved in certain neurodegenerative diseases such as Alzheimer’s disease. In particular, some metalloproteases involved with these diseases are studied and the possibility of modulating the enzymatic activity of these biomolecules for therapeutic purposes is investigated. The influence that metal ions such as copper or zinc have on the biomolecular mechanisms involved in neurodegeneration is also studied using various analytical techniques such as mass spectrometry, surface plasmon resonance, NMR, etc.

Giuseppe Grasso has authored or co-authored more than 80 papers and he has an h-index of 28. He has attended more than 60 international conferences, presenting his work either as an oral communication or as a keynote lecture.

Dr. Jeffrey M. Witkin, Ph.D., is a senior investigator in the Laboratory of Antiepileptic Drug Discovery that he founded with neurosurgeon Jodi L. Smith at Ascension, St. Vincent in Indianapolis, Indiana.  He is also an adjunct professor at the   University of Wisconsin-Milwaukee where he co-led the team to bring an a2/3-selective GABAkine, KRM-II-81, to ResprireRx Pharmaceutics Inc where he now serves as a Senior Research Fellow.  Dr. Witkin is one of the co-founders of Gilgamesh Pharmaceutics and his due diligence has help to foster several new start-up companies.  For 17 years, he directed a neuroscience discovery group at the Lilly Research Labs that discovered multiple antidepressants and novel glutamate and GABA receptor neuromodulators.  Key scientific contributions from his work have enabled the discovery and development of anxiolytics, antidepressants, and antiepileptic medicines.   Dr. Witkin’s work on AMPAkines has been one of the primary mechanistic guides to the discovery of rapid-acting antidepressants.  His laboratory was the first to disclose the antiepileptic effects of the neuroactive steroid ganaxolone that was recently approved as a medicine.  His biological leadership over the studies of LY2940094 (BTX-246040), a novel NOP receptor antagonist, led to the first proof-of-principle study of antidepressant activity in patients for this mechanism.  He is the patent holder for the invention of the antiepileptic effects of LY3130481 (ES-481), the first g-8 TARP-dependent AMPA receptor antagonist under development for intractable epilepsy.  He is most excited about bringing an mGlu2/3 receptor antagonist for IV and oral use to the scientific community.  He is a world class scientist with over 250 peer-reviewed publications, and recently edited the book, Neuropsychopharmacology, for Elsevier.  He has been awarded several invention patents and multiple scientific honors.

Vladimír Havlíček studied organic technology and received a Ph.D. in analytical chemistry at the Prague Institute of Chemical Technology. After a postdoctoral stay at the University of Washington in Seattle, he began conducting proteomics, lipidomics, and metabolomics experiments in the Czech Republic, focusing on mass spectrometry imaging and ambient ionization techniques. Since 2006 he has been appointed the Chair of the Laboratory of Molecular Structure Characterization at the Institute of Microbiology (Prague, Czech Republic), now harboring microbiology, mass spectrometry, nuclear magnetic resonance, and electron microscopy equipment. In the 2022 four-month sabbatical, he received training in analytical chemistry and infection microbiology from K.A. Schug (UTA, Texas) and D.A. Stevens (CIMR, California). In medical topics, his laboratory members provide instrumental support to research groups on campus & overseas with focus to both non-communicable and infectious diseases. Laboratory central analytical concept, named infection metallomics, exploits host-microbial consortia interactions moderated with antimicrobial therapies in the lung, central nervous system, and urogenital tract infections.

Agnieszka Zelek-Molik is an assistant professor in the Department of Brain Biochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, in Kraków, Poland. In her scientific work, she focuses primarily on studying the processes accompanying the development of mental disorders related to stress and drug addiction. She gained her scientific experience also abroad, especially at the Medical University of South Carolina, working in in JF McGinty Lab of the Neuroscience Department.

Agnieszka Chocyk, PhD is a assistant professor in the Laboratory of Pharmacology and Brain Biostructure, Department of Pharmacology of the Maj Institute of Pharmacology, Polish Academy of Sciences. Her scientific experience and interests focus on the effects of early-life stress on brain maturation and functions and the mechanisms of susceptibility and resilience to stress-related psychopathologies.

Rachel Smith is an assistant professor in the Department of Psychological and Brain Sciences at Texas A&M University in the USA. Her lab studies the behavioral neuroscience of drug addiction and is focused on understanding the behavioral and neurobiological mechanisms underlying habitual and compulsive behaviors.

Vittorio Maglione is a neuroscientist with over 25 years of research experience in molecular genetics, molecular and cellular biology and biochemistry and with the use of multiple study models (from primary cells to mouse models) in context of Huntington disease (HD) and other neurological disorders including Parkinson’s disease and Rett SynDr.ome. Vittorio Maglione has completed his PhD in Neurobiology from University of Catania (Italy) and postdoctoral studies first from Neurological Institute “IRCCS Neuromed” (Italy) and successively from University of Alberta (Canada). After he have been awarded a Marie Curie Fellowship, he became Group Leader at “Neurogenetics Lab” of IRCCS Neuromed. Dr. Maglione’s major interest is the investigation of the biochemical and genetic mechanisms underling neuronal dysfunctions and neurodegeneration. Over the last ten years Dr. Maglione’s research has demonstrated that the alterations in the metabolism of (glyco)sphingolipids are a critical determinant in the pathogenesis of HD and other neurological disorders and may represent a potential therapeutic target. Thanks to this research Dr.. Maglione filled a patent granted in USA in 2015 (US9023812B2). Other projects include the development of gene therapy as therapeutic approach for neurodegenerative diseases. Dr.. Maglione is author of more than 60 scientific peer-reviewed papers and is Associate Editor for Frontiers in Neuroscience – Neurodegeneration and Frontiers in Molecular Neuroscience. He is also Member of the “European Huntington Disease Network” (EHDN), “Huntington Study Group” (HDS) and of both European and International Neurochemistry Society (ESN and ISN). Dr. Maglione is currently the Scientific Secretary of the International Association “Sphingolipid Club”.

Professor Alessandro Prinetti, PhD was involved in research activities within the field of sphingolipid biochemistry and cell biology since 1984. His scientific personality was shaped in two of the leading laboratories worldwide in this research area: the laboratory of Sphingolipid Biochemistry at the Dept. of Medical Chemistry, Biochemistry and Biotechnology, University of Milano, under the guidance of G. Tettamanti, and the laboratory of S. Hakomori at the Dept. of Pathobiology /Pacific Northwest Research Institute, University of Washington (Seattle, WA, USA). In the early years of his scientific activity, he contributed to elucidate glycosphingolipid metabolic pathways in the nervous system, and in particular to define the metabolic mechanisms responsible for the generation of bioactive sphingolipids. More recently, his studies contributed to define the concept of lipid rafts. In particular, his research highlighted the importance of sphingolipids in modulating the generation of signals at the plasma membrane by either determining the dynamic properties of specialized membrane signaling platforms, or affecting the activity of plasma membrane signaling complexes via specific sphingolipid-protein interactions. His achievements shed a new light on the role of sphingolipids in the physiopathology of nervous system and in tumor cell biology. In particular, AP studied sphingolipid patterns, metabolism and function related to neuronal differentiation and neurodegeneration, myelin formation and repair, neoplastic transformation, tumor cell adhesion and invasiveness. His current main research projects deal with the role of sphingolipids in myelin formation and repair of damaged myelin. His scientific activity is documented by 124 papers in peer-reviewed journals or book chapters (5,987 citations, h-index: 42) and more than 100 communications to scientific meetings. Prof. Prinetti has been actively engaged in scientific societies. He has been Council Member, Secretary and President of the European Society for Neurochemistry. He has been the Chair of the Programme Committee of the 24^th ESN Biennial Meeting – 8^th Conference on Molecular Mechanisms of Regulation in the Nervous System After being Council Member and Chair of different committees within the International Society for Neurochemistry, he is now the Treasurer of ISN (2021-2025).

Justyna Barut is a PhD student in the Department of Brain Biochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, in Kraków, Poland. Her PhD thesis is about creating new transgenic mice models of the early phase of Parkinson’s disease and the involvement of noradrenergic transmission in this process. She is also interested in astrocytes and their role in the pathogenesis of Parkinson’s disease, which she investigates in her research project.

Dr. Musazzi graduated in Pharmaceutical Biotechnologies in 2004 and obtain the PhD in Pharmacological Sciences in 2008, at the University of Milano (IT). From 2009 to 2015, she worked as postdoctoral associate in the Laboratory of Neuropsychopharmacology and Functional Neurogenomics, directed by Prof. Maurizio Popoli. In 2010, she won a European College of Neuropsychopharmacology (ECNP) research grant for young scientists and spent 12 months at the Aarhus University (DK), learning stereological approaches.

From 2015 to 2018, she was Assistant Professor in Pharmacology at the University of Milan and in 2020, she became tenured Associate Professor in the University of Milano-Bicocca (Department of Medicine and Surgery). Her main research interest are the investigation of the regulation of synaptic function, neuroplasticity, and gene expression in acute/chronic stress and study of the pathogenesis of psychiatric disorders as well as mechanisms of psychotropic drugs.

She published over 60 articles in peer-reviewed international journals.

Yonatan Kupchik is an associate professor in the Department of Medical Neurobiology, IMRIC, at the Hebrew University of Jerusalem in Israel and a head of the Center for Addiction Research at the Faculty of Medicine of the Hebrew University. His lab is interested in understanding the neurobiological processes that turn normal motivated behavior into an addiction. They investigate this by combining state-of-the-art tools with behavioral models of pathological motivation to target and manipulate specific circuits in the reward system and evaluate synaptic plasticity in drug addiction and overeating.

Prof. Marta Dziedzicka-Wasylewska works at the Institute of Pharmacology, Polish Academy of Sciences, Kraków, and at the Jagiellonian Uniwersity, Faculty of Biochemistry, Biophysics and Biotechnology.

Her research interests revolve around the mechanisms of action of antidepressant and antipsychotic drugs, with a particular focus on membrane receptors important in neurotransmission, such as dopamine and serotonin receptors. Series of papers concerning heterodimerization of G protein-coupled receptors and the role of that phenomenon in the mechanism of action of various psychotropic drugs, including clozapine and antidepressant drugs have been recently awarded by the prestigious Jedrzej Śniadecki Award of Division V Medical Sciences of the Polish Academy of Sciences (2019).

More recent research is focused on mechanisms responsible for susceptibility and resilience to stress as well as on biomarkers of resilience, with a particular focus on microRNAs. In a series of papers, we’ve recently shown that certain microRNAs may serve as biomarkers of response (susceptibility or resilience) to acute and chronic stress in experimental animal models. The results in this field published in a series of papers: „Determination of the role of selected microRNAs as biomarkers of stress resilience” was awarded in 2022 by Division V Medical Sciences of the Polish Academy of Sciences with the team prize.

In her work, prof. M. Dziedzicka-Wasylewska applies methods from the scope of biochemistry, biophysics, molecular biology and cell biology as well as behavioral techniques used in psychopharmacology.

Barbara Błasiak obtained her PhD degree in physics in 2011 and habilitation in 2018. Her research focused on magnetic resonance imaging. Her career began with the rf coils design for MRI, multinuclei MR Spectroscopy and low field MRI. Currently she is working as a Professor in Institute of Nuclear Physics Department of Magnetic Resonance Imaging in Krakow. She made many foreign internships at the University of Victoria, University of Calgary and National Research of Council in Canada where she was involved in the applications of nano-technology in medicine and molecular imaging of brain, breast and prostate cancer.

Dr. Jakub Wlodarczyk obtained his PhD in Physics from Warsaw University (Poland) in 2006 and a postdoctoral training in Max Planck Institute for Biophysical Chemistry (Goettingen. Germany). Since 2012, he leads a Laboratory of Cell Biophysics at the Nencki Institute (Warsaw, Poland). In 2020 he was nominated Professor of Natural Sciences. The main field of his interest is aberrant synaptic plasticity underlying stress related disorders and stress resilience. He studies structural and functional synaptic modifications regulated by posttranslational modifications. He develops and employs novel imaging based techniques and mass spectrometry methods to assess the reorganization of activity patterns accompanied by local volumetric and molecular changes at the synapses.

Christian P. Müller was born in 1972 in Annaberg-Buchholz, a small place in former German Democratic Republic. After German reunification, he studied Psychology and Philosophy at the Universities of Düsseldorf and Oxford, UK. He obtained a Diploma in Experimental Psychology from Düsseldorf University, where he studied and worked in Joe Huston’s lab for many years. After several research visits at the Primate Center of Brasilia University, Brazil, and Syracuse University, US, he got his PhD in 2003 from Düsseldorf University and in 2006 his Habilitation. His own research focused on the serotonergic system and its role in behavior and behavioral pathologies. In 2007 he moved as a Senior Lecturer to the Institute of Psychiatry at King’s College London, UK, where he built up a rodent lab focusing on the neurobiology of psychiatric disorders, and particular drug addiction. Since 2010 he is Professor for Addiction Medicine at the University of Erlangen-Nuremberg, Germany. With that, research scope widened with a strong interest in brain lipids and translational approaches from cell systems, rodent and primate models up to human behaviors and their evolutionary origin. So far, Christian P. Müller has published more than 160 papers and book chapters (h-index: 51). He currently serves in the editorial boards of several journals, like ‘Addiction Biology’, ‘Brain Research Bulletin’, ‘Pharmacological Reports’, ‘Psychopharmacology’, and ‘Frontiers in Behavioral Neuroscience’. He is Editor-in-chief of the journal ‘Behavioural Brain Research’

Shigeyuki Chaki, PhD, received a B.S. in Pharmacy from Tokyo University of Pharmacy and Life Sciences (Tokyo, Japan) in 1985, an M.S. in Biochemistry from Tokyo University of Pharmacy and Life Sciences in 1987, and a Ph.D. in Pharmacology from Tohoku University (Miyagi, Japan) in 1995. From 1990 to 1993, he was trained at the Department of Biochemistry, Vanderbilt University School of Medicine (Nashville, TN), where he had worked on peptide GPCRs under supervision of Dr. Tadashi Inagami. He joined Taisho Pharmaceutical Co., Ltd, in 1987, and has led several projects including CRF1 receptor antagonists, V1b receptor antagonists, MCH1 receptor antagonists, mGlu2/3 receptor agonists/antagonists and glycine transporter 1 inhibitors for the treatment of depression or schizophrenia. He has been responsible for leading drug discovery and development for psychiatric disorders, such as schizophrenia, depression and anxiety at Taisho. Currently, he is Fellow at Taisho.

Dr. Chaki received a B.S. in Pharmacy from Tokyo University of Pharmacy and Life Sciences (Tokyo, Japan) in 1985, an M.S. in Biochemistry from Tokyo University of Pharmacy and Life Sciences in 1987, and a Ph.D. in Pharmacology from Tohoku University (Miyagi, Japan) in 1995. From 1990 to 1993, he was trained at the Department of Biochemistry, Vanderbilt University School of Medicine (Nashville, TN), where he had worked on peptide GPCRs under supervision of Dr. Tadashi Inagami. He joined Taisho Pharmaceutical Co., Ltd, in 1987, and has led several projects including CRF1 receptor antagonists, V1b receptor antagonists, MCH1 receptor antagonists, mGlu2/3 receptor agonists/antagonists and glycine transporter 1 inhibitors for the treatment of depression or schizophrenia. He has been responsible for leading drug discovery and development for psychiatric disorders, such as schizophrenia, depression and anxiety at Taisho. Currently, he is Fellow at Taisho.

Józef Dulak, PhD, DSc, is the professor and head of the Department of Medical Biotechnology at the Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University in Kraków, Poland. He is elected member of the Polish Academy of Arts and Sciences and  member of Academia Europaea. Currently he is the vice-chairman of the Committee of Biotechnology of the Polish Academy of Sciences. He worked as post-doctoral fellow at Free University in Amsterdam (1991), University in Muenster  (1994) and Stanford University (1997), and was the research fellow at the University of Innsbruck (1999-2001). He is the doctor honoris causa of the University of Orleans in France (2012), received the “Dr. Luis Federico Leloir” Award from the Argentinian Ministry of Science and Technology (2014), and has been invited to lecture at numerous international conferences and foreign institutions, including the visiting professorship from the Japanese Society  for the Promotion of Science (2010) and at the University of Orleans (2009, 2013).  From  2013 to 2020 he was the coordinator of the International Associated Laboratory (LIA) of the Jagiellonian University and CBM CNRS in Orleans, he was the president of the European Vascular Biology Organization (EVBO) – 2013-2017.

He conducts research on molecular mechanisms of cardiovascular diseases and genetic neuromuscular diseases, including the function of stem cells and the possibilities of genetic and cell therapies. He is the co-author of more than 280 papers (h-index is 56), and is  the co-inventor of one patent. Prof. Dulak coordinated numerous grants (more than 13,5 million Euro in the last 10 years), both research and infrastructural.

Web: https://zbm.wbbib.uj.edu.pl/en_GB/

Danilo De Gregorio obtained a Pharm.D. degree from the University of Naples “Federico II”, Italy, followed by a Ph.D. in Neuropharmacology from the University of Campania “Vanvitelli”, Naples, Italy. He trained as a postdoctoral fellow at the Department of Psychiatry, McGill University, Montreal (QC), Canada under the supervisions of Prof. Gabriella Gobbi and Prof.  Nahum Sonenberg. Since March 2021, he holds the position of Assistant Professor of Pharmacology, Vita-Salute San Raffaele University. By combining cutting-edge in vivo behavioral and electrophysiological techniques in animal models, Danilo has made contributions to the understanding of the psychopharmacology of psychoactive compounds including hallucinogens and cannabinoids and their role in mental disorders.  His work has been published in relevant scientific journals (including Nature, PNAS, Nature Communications). He has received numerous awards for his work including the Canadian Institute of Health Research (CIHR) grant and the Fonds pour la recherche en Santé du Québec.

Dr Morisset-Lopez obtained her PhD in Molecular Pharmacology from Paris V University (France) in 1999 and joined the Center of Psychiatry and Neurosciences in Paris in 2002 as CNRS (The National Center for Scientific Research) researcher. She contributed to better understand the molecular mechanisms regulating the histamine H₃ receptor activity. She is currently a senior scientist at the Center for Molecular Biophysics (Orléans, France) where she co-leads the department of Biology (BioBRAT) and heads the team « Neurobiology of receptors and therapeutic innovations” (NeuRIT).  The main field of her interest lies in G protein-coupled receptors pharmacology and neurobiological mechanisms of the pathophysiology of central nervous system disorders. Her ongoing studies concern the pharmacology of serotonin 5-HT7 receptor, its biased signalling and its role in neuro-oncology, pain and neuroinflammatory diseases such as multiple sclerosis. For that purpose, her team sets up various cellular assays, based on BRET, nanoBRET and Phage display methods for drug screening and also develops animal models of neuropathologies in mice and Drosophila in order to evaluate the therapeutic potential of new 5-HT7 ligands.

Dr. Nichols currently is a professor of pharmacology at Louisiana State University Health Sciences Center in New Orleans, LA. He earned his B.S. at Purdue University, his Ph.D. at Carnegie Mellon University, and performed his postdoctoral work at Vanderbilt University School of Medicine in the Department of Pharmacology researching. He has been studying the cellular, molecular, genetic, and behavioral effects of 5-HT2A receptor and psychedelics for over 25 years and is considered one of the world’s top experts on the biological effects of psychedelics in the brain and body. He is a founding member of the International Society for Research on Psychedelics, and its current President. He is also Co-Editor in Chief of Psychedelic Medicine. Key discoveries he and his laboratory have made include elucidation of the effects of psychedelics on gene expression in the brain, identification, and characterization of the specific cells in the brain that directly respond to psychedelics, and the development of new rodent and fruit fly experimental systems recapitulating the long-lasting antidepressant-like effects of psilocybin for mechanistic study. Dr. Nichols has also discovered that psychedelics are extremely potent anti-inflammatory agents, and can have full efficacy at levels far below those necessary to induce behavioral effects in several models of inflammatory diseases. Drug discovery efforts are currently underway in his laboratory to develop psychedelics without behavioral effects for the treatment of inflammatory diseases

Jacek Stępniewski, PhD is a post-doc at the Department of Medical Biotechnology, Jagiellonian University, Kraków, Poland. His scientific interests concern application of human induced pluripotent stem cells (hiPSC) and CRISPR/Cas9 gene editing for studying molecular basis of genetic diseases, including Duchenne and LAMA2-related muscular dystrophies. Additionally, ongoing research is focused on characterization of new factors regulating human cardiomyocytes and augmenting the therapeutic potential of hiPSC-derived cells in the treatment of myocardial infarction.

Iskra Pollak Dorocic is an Assistant Professor at Stockholm University and Science for Life Laboratory in Sweden. She obtained her PhD at Karolinska Institute studying neural connectivity of the serotonin system, and completed a postdoctoral fellowship at University of California, Berkeley where she recorded neural activity of serotonin neurons during complex behaviors. Her lab is focused on the molecular heterogeneity of neuromodulators, including serotonin and dopamine. The lab utilizes genetic and molecular profiling, neuroanatomy and connectivity mapping, in vivo imaging of neural activity, and optical neuromanipulation techniques in transgenic mice, with the goal of untangling specific components of neural circuits and studying their contribution to both healthy brain function and disease.

Professor Chen’s research mainly focuses on the pathogenesis of inflammatory vascular injury, gene and stem cell therapy research. He was the Chairman of the Department of Physiology and Pathophysiology, Shanghai College of Medicine of Fudan University, and the director of the Center for Kidney and Hypertension of Fudan University.
Professor Chen received his Bachelor’s Degree of Medicine in 1985 and Master degree of Pathophysiology in 1988 from Second Military Medical University, Shanghai, China. He served as an associate Professor of Pathophysiology at the Department of Pathophysiology of Second Military Medical University before leaving for Germany to work at Department of Experimental Surgery in University of Magdeburg School of Medicine as an Alexander von Humboldt Fellowship in 1997. In 1998, he went to United States to work at Department of Medicine in University of Florida School of Medicine. Before returning to China to work in Fudan University Shanghai College of Medicine in 2006, he was an assistant professor of internal medicine at the University of Alabama School of Medicine (Birmingham).
Professor Chen was principal investigator and co-investigator of 4 NIH research grants in the United States. In the past 5 years, he serves as principal investigator of the key project of the National Key R&D Program, grants awarded by the National Natural Science Foundation of China (key projects, major international cooperation projects, international cooperation, major research plan projects and general projects), and the National Key Basic Research and Development Program (973).
Professor Chen has published more than 90 articles in SCI journals, including Cir Res, AJT, PNAS, JASN, JEM and other journals. At present, he serves as the vice chairman of the Chinese Physiological Association, the standing director of the Chinese Pathophysiology Association and the Chinese Microcirculation Association.

Prof. Agnieszka Łoboda received her Ph.D. degree in 2006 and D.Sc. in 2015 (both in biochemistry). She is now a tenured professor and works in the Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University in Kraków. Currently, she investigates the molecular mechanisms of Duchenne muscular dystrophy. For many years, her work focused primarily on vascular biology, with a particular interest in angiogenesis, inflammation, and oxidative stress. Prof. Łoboda was awarded several prestigious awards, for example the L’Oreal Award for Women in Science (Poland edition) and the POLITYKA scholarship ‘Stay with us’ for young and talented researchers. She is the section editor of the Acta Biochimica Polonica journal, the co-editor of special issues of Cells and Biomolecules journals and the co-author of around 80 papers indexed in PubMed and several book chapters (h-index – 31, total citations – more than 4,400).

Research scientist with R&D expertise on computational cardiology and electrophysiology. He obtained his PhD on the forward and inverse problems of ECG from Karlsruhe Institute of Technology (Germany) in 2016. Before founding EPIQure GmbH in 2020 he was working as research scientist at EP Solutions SA (Switzerland) in the field of ECG imaging. Being CEO of EPIQure GmbH, Danila is taking active part in development of algorithms for automatic cardiac segmentation and personalized 12-lead ECG interpretation.

Doctor Agnieszka Wnuk is a graduate of the Jagiellonian University in Krakow (2012). In addition to bachelor and master theses, she successfully completed postgraduate study in molecular biology at the Faculty of Biochemistry, Biophysics and Biotechnology. She accomplished doctoral studies at the Institute of Pharmacology of the Polish Academy of Sciences with PhD degree in the discipline of medical biology, in 2018. The basis of the distinguished doctoral dissertation was a series of original papers which concern the discovery of molecular, including epigenetic, mechanisms of action of a chemical UV filter – Benzophenone-3 and its possible role in the etiology of the nervous system disorders. Dr Wnuk also completed internships at: the University of Zurich (2017) that was financed by the Foundation for Polish Science, the Institute of Neuroanatomy of the RWTH University in Aachen (2019) as well as the University of Perpignan in France (2021). She was awarded by the Foundation for Polish Science with START 2018 program for outstanding young scientists at the beginning of their scientific career, and by the Medical Sciences Faculty of the Polish Academy of Sciences with the Team Award (2018). The current research interests of Dr Wnuk is related to civilization diseases, such as stroke, perinatal asphyxia and Alzheimer’s disease as well as the nervous system disorders resulting from exposures to environmental pollutants. She is an author and co-author of 31 publications that were cited 429 times (H-index 18).  Moreover, she is the principal investigator of research grants (Preludium 7, Sonata 17) and a scientific supervisor of master’s and doctoral theses.

Prof. Małgorzata Kajta is the head of the Laboratory of Neuropharmacology and Epigenetics at the Maj Institute of Pharmacology of the Polish Academy of Sciences in Krakow. She completed her master’s and doctoral studies at the Jagiellonian University, and obtained her habilitation degree in medical biology at the Institute of Pharmacology of PAS (2010). She was on scientific internships in Great Britain (London, Laboratory of the Cancer Research Campaign), the United States (Washington, Georgetown University Medical Center) and Germany (Ulm, University of Ulm; Aachen, RWTH – University Clinic). In addition, prof. Kajta was appointed by the European Commission as an expert in the 7th Framework Programme for Research and the Horizon 2020. Her achievements include an award from the Journal of Cell Sciences and the British Society for Cell Biology (University of Sussex, Brighton 1992), a scholarship from the European College of Neuropsychopharmacology: Targeted Exert Meeting on Dementia and Neurodegenerative Disorders (Vienna, 2007), and the Team Award of the Medical Sciences Faculty of the Polish Academy of Sciences (Warsaw, 2018). Initially, the main area of her research ​​interests was the neuroprotective potential of estrogens, with particular emphasis on anti-apoptotic properties. Over time, she identified new signaling pathways that act as targets for environmental pollutants in the mammalian brain. Currently, prof. Kajta focuses on specific molecular mechanisms that could enable effective pharmacotherapies of ischemic stroke and Alzheimer’s disease. Up to now, she published 72 research papers which have been cited over 1700 times (H-index 29). She also is the principal investigator of research grants and a scientific supervisor of master’s and doctoral theses.

Dr Urszula Kozłowska is a doctor in biology interested in immunological aspects of degeneration and regeneration of neural tissue and the bench-to-bedside approach of novel therapeutic strategies discovery. She is currently conducting in vitro research on the influence of psychedelics on microglia immunology and neural stem cells differentiation and the in vivo application of psilocybin in the 3xTg-AD murine model of Alzheimer Disease.

I am native of Montpellier (France) and I received my PhD in Neuroscience from the University of Montpellier, I did a postdoctoral training in neuroendocrinology at the University of Portland and got a permanent position at the CNRS at the University of Montpellier.

For the past 15 years, I have been working on the molecular basis of spinal muscular atrophy (SMA). My team has used mouse cell models, motor neurons derived from human induced pluripotent stem cells (iPSCs), and muscle biopsies from healthy individuals or patients with SMA. We developped a relevant human NMJ on chip model first to study molecular defects occurring during SMA onset and to create platform for drug screening. Currently my group focused on understanding the molecular basis of spinal muscular atrophy (SMA) and we try to understand what could explain the high vulnerability of MN in the disease. We focused on a specific role of SMN on the RNA transport along axon. Using molecular tools, we address the question on how disruption of RNA transport and local translation along axon could impact the death of motoneurons and impairment of NMJ observed in SMA.

Prof. Marcin Majka graduated from the Faculty of Biology at the Adam Mickiewicz University. In 2000 he obtained a doctoral degree at the Pomeranian Medical University. From 1997 to 2003 he worked at University of Pennsylvania and University of Louisville, USA, where he conducted research on hematopoietic stem cells, HIV infection, extracellular vesicles and cancer. After returning to Poland, he participated in basic research and clinical trials, including the REGENT and CIRCULATE trials. Currently, he is employed as a professor at the Jagiellonian University in the Department of Transplantation. Prof. Majka scientific interests include stem cell biology and clinical application of various types stem cells; role of transcription factors in cancer; application of iPS cells in studying CNS diseases and CAR-T technology. Prof. Majka has published over 150 papers in international journals such as Blood, Journal of Clinical Investigation, Leukemia, Stem Cell, Stem Cell Translational Medicine, Circulation Research and European Heart Journal. Prof. Majka received numerous awards including: Scholarship of the Ministry of Science and Higher Education for outstanding young scientists; Prime Minister Award for the habilitating thesis; Team Awards of the Ministry of Health for outstanding scientific achievements. He serves as a reviewer for granting agency such as National Science Center, National Center for Research and Development, Fundacao para a Ciencia e a Tecnologia, European Research Council.

Prof. Dr. Evgeni Ponimaskin is head of the Department of Cellular Neurophysiology at the Medical School Hannover, Germany. His scientific activities are centred on the analysis of the molecular mechanisms involved in regulation of signal transduction via G-protein coupled receptors (GPCRs). The strategic aim of his research projects is understanding of time- and space-dependent interaction between receptors and their downstream effectors, leading to the specific actions under physiological and pathological conditions.  As a model system, his laboratory uses different serotonin  receptors.

Danuta Jantas is an assistant professor in the Department of Experimental Neuroendocrinology, Maj Institute of Pharmacology, Polish Academy of Sciences. She graduated in biology at the Jagiellonian University (1999) and obtained PhD in medicinal biology at the Maj Institute of Pharmacology PAS (2008). Her research interests are focused on cellular models of neurodegeneration and neuroprotection. In addition to searching for intracellular mechanisms of action of clinically used drugs, she is also interested in investigating new synthetic or natural compounds with neuroprotective or anticancer activities. In recent ten years she has been involved in realization of interdisciplinary research projects on development of polymer-based nanoparticles for brain delivery of neuroprotective substances.

Rugmani Meenambal is a Postdoctoral Research Fellow working under Marie Skłodowska-Curie Cofund PASIFIC Programme at Maj Institute of Pharmacology, Polish Academy of Sciences. Her research focus on the development of functional theranostic nanoparticles and its evaluation in various cellular models of Parkinson’s disorders. She received her Ph.D. from Pondicherry University, India, on the thesis titled „Synthesis and structural insights of Ln³⁺ doped β-Ca₃(PO₄)₂ and LnPO₄ contrast agents for multimodal imaging applications”. She is interested in design of nano-formulations for theranostic applications.

Prof. Maurilio Sampaolesi’s research team has extensive experience in the field of stem cells and their role in skeletal muscle regeneration and degeneration. Basic studies on epigenetics (methylation and histone code), miRNA signatures and single cell identity towards myogenic lineages are also main research tasks. Recently, extracellular vesicle-mediated miRNA cargo networking to interfere the muscle phenotypes and 3D cell modelling for muscular dystrophies are the most recent scientific adventures in a diverse and multidisciplinary environment for the future scientific career path.

Dr. Aron Lichtman earned his B.A. in Psychology at Rutgers College in 1984 and proceeded to earn his Ph.D. in Psychology with Drs. Michael Fanselow and Catherine Cramer at Dartmouth College in 1989. He received postdoctoral training from 1989-1993 in pharmacology under the mentorship of the late Dr. Billy R. Martin at Virginia Commonwealth University (VCU). He then joined the faculty at VCU and rose through the ranks to Professor. In 2015, Dr. Lichtman became Associate Dean for Research and Graduate Studies in the VCU School of Pharmacy, while continuing his basic research. His research program has been continuously funded by the National Institutes of Health for 30 years. The International Cannabinoid Research Society (ICRS) recognized Dr. Lichtman for outstanding research contributions with the 2013 Mechoulam Award. He also is a co-inventor on two patents for a THC metered dose inhaler, which progressed through Phase II clinical trials, and serves on the Scientific Advisory Board of Sea Pharmaceuticals as well as for Abide Therapeutics until its acquisition by H. Lundbeck A/S in May 2019. In addition to his scholarship, Dr. Lichtman is a dedicated teacher and mentor, and has trained 16 Ph.D. students, 13 postdoctoral fellows, and many high school, undergraduate, MS, and post baccalaureate students. He twice received the Professor of the Year Award from the Department of Pharmacology and Toxicology and the VCU School of Medicine recognized him with the Distinguished Mentor Award in 2013.

Dr. Lichtman’s research focuses on drug abuse, with an emphasis on the investigation of the endogenous cannabinoid system. His NIDA-supported research has resulted in the publication of over 200 peer-review articles that have revealed: 1) the physiological functions of the endogenous cannabinoid system; 2) the neural substrates and mechanisms of action underlying cannabinoid-induced behaviors; and 3) the consequences of chronic cannabinoid administration (i.e., dependence). His research utilizes a collaborative multidisciplinary approach examining the relationship between the pharmacological effects of cannabinoids on behavior and the underlying biochemical/molecular processes. His research group has provided proof of principle through complementary approaches using drugs and genetically engineered mice that the endogenous cannabinoid system contains promising therapeutic targets to treat a variety of disease states. This basic research has stimulated translational research to explore the efficacy of cannabinoid receptor agonists as well as inhibitors of endocannabinoid regulating enzymes in humans. The long-term goals of the Lichtman laboratory include increasing basic understanding of the physiological functions of the endogenous cannabinoid system and the consequences of acute and chronic cannabis on the brain, as well as to contribute to the development of cannabinoid-based medications for the treatment of pain and inflammatory disorders, psychiatric conditions, and drug addiction.

Professor Radosław Zagożdżon graduated from the First Faculty of Medicine, Medical University of Warsaw in 1996. He received his doctoral degree (PhD, Hons) in medical sciences in 1998 from the Center of Biostructure, MUW. In the years 1997‒2000, he worked as a physician in the Department of Immunotherapy, Transplantology and Internal Medicine, Transplantation Institute, MUW. In 1999, he received the first degree of specialization in internal medicine. In the years 1999‒2000, he worked as an adjunct in the Department of Immunology, Center for Biostructure, MUW. In the years 2000‒2005, he was employed as a Postdoctoral Fellow and, subsequently, (2005‒2008) an Instructor in Medicine in Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School in Boston, USA. In the years 2008-2012, he worked as a Postdoctoral Fellow/Occasional Lecturer at University College Dublin in Ireland. Between 2016-2016, he has been the leader of the bioinformatics group at the Department of Immunology, Medical University of Warsaw under the BASTION program. Since 2017, Dr. Zagożdżon is a Head of Department of Clinical Immunology, Medical University of Warsaw.

Dr Zagożdżon is the author or co-author of numerous scientific publications, both original and review papers, as well as book chapters. Dr Zagożdżon received the award of the Polish Prime Minister for his doctoral thesis. Research conducted by Dr Zagożdżon has been supported by prestigious fellowships from the Foundation for Polish Science, US Department of Defense or the Marie-Curie funding under the Seventh Framework Program from the European Union, and also by grants from National Science Centre, Poland.

Professor Joanna H. Sliwowska is a graduate of the Faculty of Biology at the University of Adam Mickiewicz in Poznań (UAM). She completed her master’s thesis in cooperation with the Medical Academy in Poznań (currently Medical University). She received her Ph.D. in animal physiology at the Adam Mickiewicz University and her post-doctoral degree at the University of Gdańsk. She obtained the title of a Full professor in 2020.

Prof. Śliwowska completed several scientific internships (Stockholm University in Sweden, Oregon University, USA; the University of Cincinnati in the USA, British Columbia University in Vancouver in Canada, Hungarian Academy of Sciences in Budapest, INRA, Nouzilly in France). She has also received several awards and scholarships (award of the City of Poznań for Young Scientists, Bluma Tischler Postdoctoral Fellowship in Canada, a scholarship under The Integrated Mentor Program in Addiction Research Training – IMPART from the Canadian Institute of Health Research, Dekaban foundation scholar – visiting professor at Canada). She participated in implementing scientific grants from the National Institute of Health (USA) and the Canadian Institute of Health Research.

In the period after her doctorate, during her stay in the USA and Canada (over eight years), the scientific interests of prof. dr hab. Śliwowska focused on issues related to the neurohormonal regulation of the hypothalamic-pituitary-gonadal and hypothalamic-pituitary-adrenal axis, the influence of alcohol on the neuroendocrine system, and neurogenesis in the hippocampus.

Currently, she is a head of the Laboratory of Neurobiology at the Faculty of Veterinary Medicine and Animal Sciences at the Poznań University of Life Sciences (UPP). Her group conducts research on the effects of diabetes and obesity on reproductive and metabolic functions, financed from grants from the National Science Centre. She is also the chairperson of the Biological Sciences discipline at UPP.

In addition to scientific activity, prof. dr hab. Śliwowska teaches classes for students of biology, neurobiology, veterinary medicine, and zootechnics. She took part in the „Teaching Science and Teaching Practice” course at Bradford and Ilkley Community College, UK, and performed teaching practice at Addingham Middle School, UK. She participated in the ERASMUS program at the University of Aberdeen, UK, and Vasco da Gama University in Portugal). Prof. Śliwowska popularizes science by publishing papers and preparing podcasts on the „Nauka to lubię” platform. She worked as an expert and reviewer in grant panels at the National Science Center and NAWA and acted as a reviewer in the European Commission Horizon 2020 program.

Dr. Adib Zendedel is a research assistant at the Institute of Neuroanatomy of RWTH Aachen University in Germany. After completing his bachelor’s and master’s studies at the University of Tehran, he defended his PhD (2012) and then moved to Germany, where he obtained the habilitation degree (2020) at RWTH Aachen University. His scientific profile includes medicine and neurobiology, with particular emphazis on oxidative stress and neuroinflammation during ischemic stroke and spinal cord injury. Dr. Zendedel successfully implemented animal models such as transient middle cerebral artery occlusion (tMCAO) and contusion model of spinal cord injury to identify inflammasome-dependent mechanisms of inflammatory processes in the mammalian nervous system. At present, Dr. Zendedel focuses on Nrf2- and miRNA-specific signaling in the early phase of spinal cord injury. In addition, he has experience in teaching anatomy and neuroanatomy, for which he received the RWTH Prize “Digital Teaching in the Curriculum” award (2020). He succeed in gaining funds for the research and was a scientific supervisor of bachelor, master’s and doctoral theses. His publication record consists of 58 papers which have been cited over 2150 times (H-index 26).

In my research, I am focused on the molecular changes in the brain caused by morphine administration. During the first steps of my studies, I used a proteomic approach to identify protein changes during morphine addiction. A primary cell culture model (astrocytes and neurons) was my first goal for this purpose. The next step of my studies was devoted to combining the results of different proteomics research to find the common metabolic pathways for this phenomenon. It appeared that metabolic energy pathways are affected the most during morphine administration. For the last few years, I have been trying to use the mass spectrometry imaging approach to go deeper into the secrets of the addicted brain. Mass spectrometry imaging offers a great possibility for molecular analysis of the tissue with preserved spatial organization, which is very important in the case of brain analysis. This technique is vulnerable to many variabilities connected with sample preparation. Still, we hope that after the tiering optimization process, we will be able to engage this technique toward our goals. During my lecture, I would like to present the method for cholesterol and glucose analysis using the mass spectrometry imaging approach.

Bozena Kaminska is head of the Laboratory of Molecular Neurobiology at the Nencki Institute of Experimental Biology of the Polish Academy of Sciences in Warsaw, Poland. She obtained her PhD in biochemistry at the Nencki Institute in 1991 and after postdoctoral training at the Mc Gill University in Montreal, Canada, she become a full professor in 2003 at the Nencki Institute and the director of the Postgraduate School of Molecular Medicine of the Medical University of Warsaw (from 2009). She was a visiting researcher at the Brain Research Institute at UCLA in Los Angeles, USA and the Nanshan Scholar professor at the Medical University of Guangzhou, China. She is an elected member of the Polish Academy of Sciences (2016) and European Molecular Biology Organization (2022). In 2021 she received a prestigious Foundation for Polish Science Award in life sciences.

She specializes in molecular neurobiology, neuro-oncology and neuroimmunology, with focus on functions of microglia. Prof. Kaminska’s lab employs multidisciplinary approaches combining in vivo experiments in rodent models of human pathologies and in vitro experiments in primary cultures, cerebral organoids and human induced pluripotent stem cells organoids. She has pioneered single-cell omics studies of brain tumor microenvironment in experimental gliomas. In recent years her group has been exploring transcriptional and epigenetic mechanisms in microglia in response to environmental exposures and experience.

Centre Interdisciplinaire de Nanoscience de Marseille, Aix-Marseille University, CNRS, France

Email : ling.peng@univ-amu.fr

The application of nanotechnology is widely expected to bring breakthrough for cancer diagnosis and treatment.¹ Dendrimers are ideal materials for elaborating nanomedicine by virtue of their well-defined structure, multivalent cooperativity and nanosize per se. I will present our recent studies on modular and adaptive dendrimer nanosystems, constructed via self-assembling of amphiphilic dendrimers,² for the delivery of imaging agents,³ anticancer drugs⁴ and nucleic acid therapeutics⁵ in cancer detection and treatment. The self-assembling approach to create supramolecular dendrimer is completely novel in concept yet easy to implement in practice, offering a fresh perspective for exploiting the advantageous features of supramolecular dendrimers in biomedical applications.

Dr Ling PENG is a research director at the French National Scientific Research Center (CNRS) and a distinguished member of the French Chemical Society. She is working actively at the interface of chemistry and biology in the conception, synthesis and evaluation of dendrimer nanosystems for biomedical applications, in particular for the delivery of drugs, nucleic acids and imaging agents in the diagnosis and treatment of cancer and infectious diseases.

MD, PhD
Gaucher Unit
Department of Medicine
Shaare Zedek Medical Center
Jerusalem, Israel
Associate Professor of Medicine
Hebrew University and Hadassah Medical School

Professor Ari Zimran was the Founder and the Director of the Gaucher Unit at Shaare Zedek Medical Center in Jerusalem, Israel from 1990 to 2018, and is currently a senior physician at the Unit. This is the world’s largest referral centre for Gaucher disease (GD), where more than 900 patients have been followed, and about 350 patients are treated with enzyme replacement therapy.

Professor Zimran developed his interest in GD during his fellowship at the Scripps Research Institute, Department of Molecular and Experimental Medicine, in La Jolla, California, USA under the mentorship of Professor Ernest Beutler.

Professor Zimran has published more than 340 professional papers and reviews and has edited three books; he has been a leader in clinical trials for new treatments for GD, including Cerezyme™, Zavesca™, VPRIV™, Elelyso™ and Cerdelga™.

Professor Zimran was the first to report the possible association between GD and Parkinson, and currently he is currently planning a clinical trial using high-dose ambroxol for the prevention and treatment of PD and additional indications.

Klaudia Proniewska leads the EU Project MRAME (Mixed Reality supporting Advanced Medical Education – New method of teaching medical skills) and other national grants connecting with advanced 3D visualization supported by mixed reality. She is Deputy Director of the Center for Digital Medicine and Robotics at Jagiellonian University Medical College, intensively working on the implementation of innovative methods of 3D visualization of medical data based on Mixed Reality technologies and 3D space mapping. A research work as part of an internship at the Thoraxcenter Heart Disease Center, Erasmus MC, Rotterdam, the Netherlands, and American Cardiovascular Research Foundation in New York results of research carried out at new ideas of teaching methods with advanced 3D visualization in cardiac field.

Peter van Dam, Cardiac Modeling specialist, visiting professor at Jagiellonian University Medical College, Center for Digital Medicine and Robotics, currently working on improving the clinical value of the 12-lead ECG through the use of inverse cardiac modeling combined with digital technologies. Inventor of a number of patented technologies that improve both the clinical and economic features of the 12-lead ECG. Academic and research international experience e.g: UT Twente, the Netherlands-teaching position on cardiac modeling; UMC Utrecht, the Netherlands-Research position on cardiac modeling; UCLA, Los Angeles, USA – Faculty position at the Cardiac arrhythmia group focusing on improving both the invasive and non-invasive mapping of cardiac arrhythmias. In the past decade, several academic educational tools have been developed (see ecgsim.org, circadapt.org, and peacs.nl). This background will support the development process of this new academic educational tool.

Prof. Horowitz graduated from the Weizmann Institute. Following a postdoctoral fellowship at MIT, Massachusetts, USA, she joined the Weizmann Institute. In 1985 she initiated studies aiming at understanding the molecular mechanisms underlying Gaucher disease. From 1990 she is at Tel Aviv University where she has continued her studies on the molecular mechanisms underlying Gaucher disease and lately on the association between Gaucher disease and Parkinson disease and misfolding in lysosomal diseases, using Drosophila as an animal model. Her lab showed that the mutant GBA1-encoded enzyme (GCase) is misfolded in the ER which activates the Unfolded Protein Response. The lab documented that expression of human mutant misfolded GCase in the fly leads to development of parkinsonian signs, which are ameliorated by chaperones.

Christine Serratrice attended university in Marseille, France and completed an internship in Internal Medicine with a master degree in immunology, and she obtained a Privat Docent from Geneva University in 2022.

Her research interests primarily lie in auto immune diseases, lysosomal diseases, and mainly Gaucher’s disease. She is an assistant head in the department of internal medicine at Geneva University Hospital and she is affiliated with several professional organizations such as the French National Society of internal Medicine, the French Committee for evaluation and treatment of Gaucher disease, the French Study Group “lysosomal disease and internal medicine”, and the International Working Group on Gaucher Disease.

She has also developed a therapeutic patient education program for Gaucher disease in France, and she participates in several international research projects related to this disease.

Krzysztof Szczepanowicz is an associate professor and the head of the Soft Matter Nanostructures Research Group at the Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Science (PAS). He graduated in polymer chemistry at the faculty of Chemistry at Jagiellonian University (2004) and obtained Ph.D. in chemistry at Jerzy Haber Institute of Catalysis and Surface Chemistry PAS (2010). His research interests are focused on surface chemistry and dispersed systems. Investigations concentrate on encapsulating active chemical compounds, nanostructured coatings, and their application for bio-materials, including drug delivery systems.

Juan Yang, Ph. D, senior scientist at Process Chemistry and Functional Materials, SINTEF Industry, Norway. She received her Ph. D at Department of Materials Science and Engineering, Zhejiang University from China in 1996. Before joined SINTEF, she has carried out post-doc research on nanotechnology at University of Aveiro in Portugal and University of Oslo.

Juan Yang has strong competences on so-gel chemistry and development of multifunctional nanomaterials including nanoparticles, nano-capsules, POSS hybrid materials and smart coatings for different applications. During the last 5 years, she has been focused on exploration of the functionalized POSS as new additives for a variety of applications such as anti-corrosion and antifouling coatings, green lubricants, new binders for the paints and drug delivery systems. She has led/task-led more than 10 national and international projects. She has been the coordinator/co-ordinator of several ERA-NET projects.

Juan Yang is the author/co author of over 50 peer review international journal papers, and has given invited lectures and oral conference presentations, and  2 international patents.

Marta Gawin graduated from the Faculty of Chemistry of the Jagiellonian University in Krakow with specialization in chemical analytics. In 2010, she defended her doctoral dissertation at the Department of Analytical Chemistry, Faculty of Chemistry, Jagiellonian University, and started working at the Laboratory of High-Resolution Mass Spectrometry of the Faculty of Chemistry, Jagiellonian University, where she analyzed low and high molecular weight compounds using MALDI time-of-flight mass spectrometry technique. In April 2015, she joined the Laboratory of Clinical Proteomics at the Center for Translational Research and Molecular Biology of Cancer of Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology Gliwice Branch, where she worked as a post-doctoral researcher in scientific projects focused on mass spectrometry-based proteomic research. From 2020 she is an assistant professor at the Center for Translational Research and Molecular Biology of Cancer. Marta’s main interests include application of MALDI mass spectrometry imaging in cancer research, and advanced methods of preparation of various types of biological samples for mass spectrometry-based proteomic analysis.

Citizenship: Canadian
Date of birth: 14/09/1976, at St. John’s, Canada
Present position: Professor of Medicine
Address: Institute for Experimental Medical Research
University of Oslo & Oslo University Hospital Ullevål
4. etg. Bygg 7, Kirkeveien 166
0407 Oslo, Norway
Contact: Phone: +47 47 34 95 95
Fax: +47 23 01 67 99
E-mail: w.e.louch@medisin.uio.no
ORCID ID: 0000-0002-0511-6112

Prof. Wieslaw L. Nowinski, D.Sc., Ph.D. represents Sano Centre for Computational Personalised Medicine, Krakow, Poland. Scientist, innovator, entrepreneur, manager, pioneer, and visionary; science-medicine-art „bridge builder”; creator of „world’s most gorgeous” human brain atlases. Affiliated with four of the world’s top 10 universities (according to the Shanghai domain ranking), No 2 in MED (the USA) and No 2, 6, and 9 in ENG (Singapore and China). He has 594 scientific publications (h-index 51, i10-index 187 (Google Scholar)), within the world’s top 2% of scientists (Stanford list)); 71 patents granted (23 US, 11 EP) and 68 patent applications filed (19 US, 21 EP). Created with his team 35 brain atlas products licensed to 67 companies and institutions, distributed in about 100 countries. Conferred with 45 awards, 30 from leading medical societies (two radiological Oscars, Pioneer in Medicine) and 3 for innovation (2014 European Inventor of the Year (within the top three)); named The Outstanding Pole in the world in 2012. Commemorated on a stamp issued by the Polish Post in 2018 to honor Polish inventors of the century (within two living inventors).

www.WieslawNowinski.com

www.nowinbrain.org

https://pl.wikipedia.org/wiki/Wiesław_Nowiński